Thermo Fisher acquires Affinity BioReagents

Thermo Fisher Scientific, a leader in serving science, says that it has acquired fellow USA-based Affinity BioReagents, a provider of antibodies, peptides, proteins and other reagents for life science research. Financial terms of the deal were not disclosed.

"Affinity BioReagents is an ideal complement to our existing capabilities in protein research," said Marijn Dekkers, chief executive of Thermo Fisher. "This acquisition enhances our extensive antibody portfolio, which will drive growth as we combine these reagents with our current proteomics offerings to create end-to-end solutions for widely used protein-research applications," he added. Such applications include Western blotting, ELISA, immuno-histochemistry, flow cytometry and mass spectroscopy.

Affinity BioReagents has an offering of more than 35,000 reagents - primarily monoclonal and polyclonal antibodies - which are used in numerous fields of medical and academic research, as well as drug discovery. The company also provides recombinant proteins and custom antibody production services. Affinity BioReagents had annual revenues of around $6.0 million in 2007, and will be integrated into Thermo Fisher's Analytical Technologies Segment.